5440-41-5 Usage
General Description
2-acetamidodecanoic acid is a chemical compound also known as N-acetyldecanoyl glycine. It is an acetylated derivative of decanoic acid and is found in the biosynthesis of lipids. 2-acetamidodecanoic acid is a fatty acid amide and is involved in various biochemical and metabolic pathways. It has been identified as a component of human skin lipids and is also found in human sweat. Furthermore, it has been studied for its potential role in inflammation and immune response modulation, making it a compound of interest in pharmaceutical and medical research.
Check Digit Verification of cas no
The CAS Registry Mumber 5440-41-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,4,4 and 0 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 5440-41:
(6*5)+(5*4)+(4*4)+(3*0)+(2*4)+(1*1)=75
75 % 10 = 5
So 5440-41-5 is a valid CAS Registry Number.
InChI:InChI=1/C12H23NO3/c1-3-4-5-6-7-8-9-11(12(15)16)13-10(2)14/h11H,3-9H2,1-2H3,(H,13,14)(H,15,16)
5440-41-5Relevant articles and documents
Studies on Angiotensin Converting Enzyme Inhibitors. 4. Synthesis and Angiotensin Converting Enzyme Inhibitory Activities of 3-Acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic Acid Derivatives
Hayashi, Kimiaki,Nunami, Ken-ichi,Kato, Jyoji,Yoneda, Naoto,Kubo, Masami,et al.
, p. 289 - 297 (2007/10/02)
(4S)-1-Alkyl-3-acyl>-2-oxoimidazolidine-4-carboxylic acid derivatives (3) were prepared by two methods.Their angiotensin converting enzyme (ACE) inhibitory activities and antihypertensive effects were evaluated, and the structure-activity relationships were discussed.The dicarboxylic acids 3a-n possessing S,S,S configuration showed potent in vitro ACE inhibitory activities with IC 50 values of 1.1x10-8-1.5x10-9 M.The most potent compound in this series, monoester 3p, had an ID 50 value of 0.24 mg/kg, po for inhibition of angiotensin I induced pressor response in normotensive rats and produced a dose-dependent decrease in systolic blood pressure of spontaneously hypertensive rats (SHRs) at doses of 1-10 mg/kg, po.